RVMD: Revolution Medicines Inc. Stocks News on December 22, 2024

One Revolution Medicines Insider Raised Their Stake In The Previous Year

RVMD

Simply Wall St.

10 days ago

One Revolution Medicines Insider Raised Their Stake In The Previous Year

RVMD

MT Newswires

16 days ago

Wedbush Cuts Price Target on Revolution Medicines to $67 From $70, Keeps Outperform Rating

RVMD

MT Newswires

17 days ago

Revolution Medicines Closes Offering of 16.6 Million Shares

Revolution Medicines Announces Closing of Upsized Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of Underwriters' Option to Purchase Additional Shares

RVMD

GlobeNewswire

17 days ago

Revolution Medicines Announces Closing of Upsized Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of Underwriters' Option to Purchase Additional Shares

Revolution Medicines price target raised to $87 from $82 at Guggenheim

RVMD

TipRanks

18 days ago

Revolution Medicines price target raised to $87 from $82 at Guggenheim

RVMD

MT Newswires

18 days ago

Revolution Medicines Prices $45 Million Stock, Warrant Offering

Revolution Medicines Announces Pricing of Upsized $750.0 Million Public Offering of Common Stock and Pre-Funded Warrants

RVMD

GlobeNewswire

18 days ago

Revolution Medicines Announces Pricing of Upsized $750.0 Million Public Offering of Common Stock and Pre-Funded Warrants

RVMD

MT Newswires

20 days ago

Revolution Medicines Launches $600 Million Offering of Common Shares

Revolution Medicines Announces Commencement of Public Offering of Common Stock

RVMD

GlobeNewswire

20 days ago

Revolution Medicines Announces Commencement of Public Offering of Common Stock

RVMD

MT Newswires

20 days ago

Stifel Raises Price Target on Revolution Medicines to $80 From $70, Maintains Buy Rating

RVMD

MT Newswires

20 days ago

Revolution Medicines Reports Early Data Supporting Ongoing Study of Cancer Therapies

Revolution Medicines Provides Clinical Updates from its RAS(ON) Inhibitor Portfolio

RVMD

GlobeNewswire

20 days ago

Revolution Medicines Provides Clinical Updates from its RAS(ON) Inhibitor Portfolio

Revolution Medicines to Host RAS(ON) Inhibitor Clinical Update Webcast on December 2, 2024

RVMD

GlobeNewswire

25 days ago

Revolution Medicines to Host RAS(ON) Inhibitor Clinical Update Webcast on December 2, 2024

RVMD

GuruFocus.com

a month ago

Decoding Revolution Medicines Inc (RVMD): A Strategic SWOT Insight

RVMD

MT Newswires

a month ago

Revolution Medicines Q3 Loss Narrows; Reaffirms Full-Year Guidance

RVMD

GuruFocus.com

a month ago

Revolution Medicines Inc (RVMD) Q3 2024 Earnings Call Highlights: Strategic Advances Amid ...

Revolution Medicines Reports Third Quarter 2024 Financial Results and Update on Corporate Progress

RVMD

GlobeNewswire

2 months ago

Revolution Medicines Reports Third Quarter 2024 Financial Results and Update on Corporate Progress

RVMD

MT Newswires

2 months ago

Revolution Medicines Insider Sold Shares Worth $3,878,773, According to a Recent SEC Filing

Revolution Medicines to Participate in Upcoming Investor Conferences

RVMD

GlobeNewswire

2 months ago

Revolution Medicines to Participate in Upcoming Investor Conferences

RVMD

GuruFocus.com

2 months ago

Revolution Medicines Inc (RVMD) Q3 2024 Earnings Report Preview: What To Look For

Revolution Medicines to Report Financial Results for Third Quarter 2024 After Market Close on November 6, 2024

RVMD

GlobeNewswire

2 months ago

Revolution Medicines to Report Financial Results for Third Quarter 2024 After Market Close on November 6, 2024

RVMD

MT Newswires

2 months ago

Revolution Medicines Says Potential Pancreatic Cancer Treatment Shows 'Encouraging' Initial Results

Revolution Medicines Presents Initial Data from RMC-9805 Monotherapy Study in Patients with Advanced Pancreatic Ductal Adenocarcinoma

RVMD

GlobeNewswire

2 months ago

Revolution Medicines Presents Initial Data from RMC-9805 Monotherapy Study in Patients with Advanced Pancreatic Ductal Adenocarcinoma

Revolution Medicines Presents Updated Data from RMC-6236 Monotherapy Study in Patients with Advanced Pancreatic Ductal Adenocarcinoma

RVMD

GlobeNewswire

2 months ago

Revolution Medicines Presents Updated Data from RMC-6236 Monotherapy Study in Patients with Advanced Pancreatic Ductal Adenocarcinoma

RVMD

MT Newswires

2 months ago

Revolution Medicines Doses First Patient in Phase 3 Study of Pancreatic Cancer Drug

Revolution Medicines Announces First Patient Dosed in Phase 3 Study Evaluating RMC-6236 in Previously Treated Patients with Metastatic Pancreatic Ductal Adenocarcinoma

RVMD

GlobeNewswire

2 months ago

Revolution Medicines Announces First Patient Dosed in Phase 3 Study Evaluating RMC-6236 in Previously Treated Patients with Metastatic Pancreatic Ductal Adenocarcinoma

RVMD

MT Newswires

2 months ago

Revolution Medicines Insider Sold Shares Worth $824,804, According to a Recent SEC Filing

RVMD

MT Newswires

2 months ago

Revolution Medicines Insider Sold Shares Worth $1,510,773, According to a Recent SEC Filing

RVMD

MT Newswires

2 months ago

Revolution Medicines Insider Sold Shares Worth $2,517,055, According to a Recent SEC Filing

Revolution Medicines to Deliver Multiple Presentations at the 2024 AACR-NCI-EORTC Symposium and Host Investor Webcast

RVMD

GlobeNewswire

2 months ago

Revolution Medicines to Deliver Multiple Presentations at the 2024 AACR-NCI-EORTC Symposium and Host Investor Webcast

RVMD

MT Newswires

3 months ago

Revolution Medicines Insider Sold Shares Worth $517,631, According to a Recent SEC Filing

RVMD

MT Newswires

3 months ago

89bio Appoints Teresa Perney as Chief Regulatory, Quality Officer

RVMD

Insider Monkey

3 months ago

Revolution Medicines, Inc. (RVMD): Among Hedge Funds’ Top Biotech Stock Picks

RVMD

MT Newswires

4 months ago

Revolution Medicines Insider Sold Shares Worth $716,389, According to a Recent SEC Filing

Revolution Medicines First Half 2024 Earnings: US$1.51 loss per share (vs US$1.64 loss in 1H 2023)

RVMD

Simply Wall St.

4 months ago

Revolution Medicines First Half 2024 Earnings: US$1.51 loss per share (vs US$1.64 loss in 1H 2023)

RVMD

Thomson Reuters StreetEvents

4 months ago

Q2 2024 Revolution Medicines Inc Earnings Call

RVMD

MT Newswires

4 months ago

Revolution Medicines Q2 Loss Narrows

Revolution Medicines Reports Second Quarter 2024 Financial Results and Update on Corporate Progress

RVMD

GlobeNewswire

4 months ago

Revolution Medicines Reports Second Quarter 2024 Financial Results and Update on Corporate Progress

RVMD

MT Newswires

5 months ago

Revolution Medicines Insider Sold Shares Worth $458,827, According to a Recent SEC Filing

Collegium Pharmaceutical (COLL) Earnings Expected to Grow: Should You Buy?

RVMD

Zacks

5 months ago

Collegium Pharmaceutical (COLL) Earnings Expected to Grow: Should You Buy?

Revolution Medicines to Report Financial Results for Second Quarter 2024 After Market Close on August 7, 2024

RVMD

GlobeNewswire

5 months ago

Revolution Medicines to Report Financial Results for Second Quarter 2024 After Market Close on August 7, 2024

RVMD

MT Newswires

5 months ago

Barclays Adjusts Price Target on Revolution Medicines to $54 From $52, Maintains Overweight Rating

RVMD

MT Newswires

5 months ago

UBS Adjusts Price Target on Revolution Medicines to $65 From $40, Maintains Buy Rating

RVMD

MT Newswires

5 months ago

Revolution Medicines Insider Sold Shares Worth $1,576,322, According to a Recent SEC Filing

RVMD

MT Newswires

5 months ago

Needham Adjusts Revolution Medicines Price Target to $62 From $46, Maintains Buy Rating

RVMD

MT Newswires

5 months ago

HC Wainwright Raises Price Target on Revolution Medicines to $56 From $44, Maintains Buy Rating

RVMD

MT Newswires

5 months ago

Oppenheimer Adjusts Revolution Medicines Price Target to $55 From $45, Maintains Outperform Rating

RVMD

MT Newswires

5 months ago

Revolution Medicines Projects 2024 Net Loss of $560 Million to $600 Million; Provides Latest Cancer Drug Study Data

RVMD

MT Newswires

5 months ago

Wedbush Raises Price Target on Revolution Medicines to $59 From $46, Maintains Outperform Rating

Revolution Medicines firms up Phase 3 trial plans with latest cancer drug data

RVMD

BioPharma Dive

5 months ago

Revolution Medicines firms up Phase 3 trial plans with latest cancer drug data

RVMD

MT Newswires

5 months ago

Barclays Initiates Revolution Medicines at Overweight With $52 Price Target

$Revolution Medicines Announces Publication Demonstrating Robust Anti-Tumor Activity of RAS(ON) Inhibitors in Preclinical Models of Refractory KRAS-Mutated Non-Small Cell Lung Cancer$

RVMD

GlobeNewswire

5 months ago

Revolution Medicines Announces Publication Demonstrating Robust Anti-Tumor Activity of RAS(ON) Inhibitors in Preclinical Models of Refractory KRAS-Mutated Non-Small Cell Lung Cancer

RVMD

Zacks

5 months ago

Revolution Medicines (RVMD) Moves 11.0% Higher: Will This Strength Last?

Revolution Medicines to Provide Update on RMC-6236 Pancreatic Ductal Adenocarcinoma Clinical Program on July 15, 2024

RVMD

GlobeNewswire

5 months ago

Revolution Medicines to Provide Update on RMC-6236 Pancreatic Ductal Adenocarcinoma Clinical Program on July 15, 2024

RVMD

MT Newswires

5 months ago

Jefferies Initiates Revolution Medicines at Buy With $63 Price Target

RVMD

GuruFocus.com

6 months ago

Insider Sale: COO Margaret Horn Sells Shares of Revolution Medicines Inc (RVMD)

RVMD

MT Newswires

6 months ago

Revolution Medicines Insider Sold Shares Worth $446,770, According to a Recent SEC Filing

RVMD

Simply Wall St.

6 months ago

Shareholders Will Most Likely Find Revolution Medicines, Inc.'s (NASDAQ:RVMD) CEO Compensation Acceptable

RVMD

MT Newswires

7 months ago

Revolution Medicines Insider Sold Shares Worth $299,942, According to a Recent SEC Filing

Revolution Medicines to Participate in Goldman Sachs 45th Annual Global Healthcare Conference

RVMD

GlobeNewswire

7 months ago

Revolution Medicines to Participate in Goldman Sachs 45th Annual Global Healthcare Conference

Revolution Medicines Reports Q1 2024 Financial Results: Challenges and Strategic Advances in ...

RVMD

GuruFocus.com

7 months ago

Revolution Medicines Reports Q1 2024 Financial Results: Challenges and Strategic Advances in ...

Revolution Medicines First Quarter 2024 Earnings: US$0.70 loss per share (vs US$0.72 loss in 1Q 2023)

RVMD

Simply Wall St.

7 months ago

Revolution Medicines First Quarter 2024 Earnings: US$0.70 loss per share (vs US$0.72 loss in 1Q 2023)

RVMD

Insider Monkey

7 months ago

Revolution Medicines, Inc. (NASDAQ:RVMD) Q1 2024 Earnings Call Transcript

RVMD

MT Newswires

7 months ago

Wedbush Raises Price Target on Revolution Medicines to $46 From $42, Maintains Outperform Rating

RVMD

GuruFocus.com

7 months ago

Revolution Medicines Inc (RVMD) (Q1 2024) Earnings Call Transcript Highlights: Strategic ...

RVMD

MT Newswires

7 months ago

Revolution Medicines Q1 Net Loss Narrows

Revolution Medicines Reports First Quarter 2024 Financial Results and Update on Corporate Progress

RVMD

GlobeNewswire

7 months ago

Revolution Medicines Reports First Quarter 2024 Financial Results and Update on Corporate Progress

RVMD

GuruFocus.com

8 months ago

Insider Sale: CFO Jack Anders Sells 10,000 Shares of Revolution Medicines Inc (RVMD)

Revolution Medicines to Report Financial Results for First Quarter 2024 After Market Close on May 8, 2024

RVMD

GlobeNewswire

8 months ago

Revolution Medicines to Report Financial Results for First Quarter 2024 After Market Close on May 8, 2024

Revolution Medicines Announces Publication on the Discovery of and Translational Research for RMC-6236, an Investigational RAS(ON) Multi-Selective Tri-Complex Inhibitor Designed to Block Full Spectrum of Oncogenic RAS(ON) Proteins

RVMD

GlobeNewswire

8 months ago

Revolution Medicines Announces Publication on the Discovery of and Translational Research for RMC-6236, an Investigational RAS(ON) Multi-Selective Tri-Complex Inhibitor Designed to Block Full Spectrum of Oncogenic RAS(ON) Proteins

RVMD

GlobeNewswire

8 months ago

Revolution Medicines Announces Publications on the Discovery and Preclinical Profile of Representative of a New Class of RAS(ON) Multi-Selective Inhibitors Designed to Block Full Spectrum of Oncogenic RAS(ON) Proteins

RVMD

GlobeNewswire

9 months ago

Revolution Medicines to Participate in Upcoming Investor Conferences

Revolution Medicines to Deliver Multiple Presentations at the Upcoming American Association for Cancer Research Annual Meeting 2024

RVMD

GlobeNewswire

9 months ago

Revolution Medicines to Deliver Multiple Presentations at the Upcoming American Association for Cancer Research Annual Meeting 2024

RVMD

Insider Monkey

10 months ago

Revolution Medicines, Inc. (NASDAQ:RVMD) Q4 2023 Earnings Call Transcript

Revolution Medicines Full Year 2023 Earnings: Misses Expectations

RVMD

Simply Wall St.

10 months ago

Revolution Medicines Full Year 2023 Earnings: Misses Expectations

RVMD

Thomson Reuters StreetEvents

10 months ago

Q4 2023 Revolution Medicines Inc Earnings Call

RVMD

Zacks

10 months ago

Revolution Medicines, Inc. (RVMD) Reports Q4 Loss, Lags Revenue Estimates

RVMD

GuruFocus.com

10 months ago

Revolution Medicines Inc (RVMD) Reports Earnings: R&D Investments Surge Amidst Clinical Progress

Revolution Medicines Reports Fourth Quarter and Full Year 2023 Financial Results and Update on Corporate Progress

RVMD

GlobeNewswire

10 months ago

Revolution Medicines Reports Fourth Quarter and Full Year 2023 Financial Results and Update on Corporate Progress

Revolution Medicines to Report Financial Results for Fourth Quarter and Full Year 2023 After Market Close on February 26, 2024

RVMD

GlobeNewswire

10 months ago

Revolution Medicines to Report Financial Results for Fourth Quarter and Full Year 2023 After Market Close on February 26, 2024

RVMD

GlobeNewswire

a year ago

Revolution Medicines to Participate in Upcoming Investor Conferences

Crocs, Inc. Announces Conference Call to Review Fourth Quarter 2023 Earnings Results

RVMD

PR Newswire

a year ago

Crocs, Inc. Announces Conference Call to Review Fourth Quarter 2023 Earnings Results

Ryder Completes Acquisition of Cardinal Logistics

RVMD

Business Wire

a year ago

Ryder Completes Acquisition of Cardinal Logistics

RVMD

Argus Research

a year ago

Analyst Report: Zions Bancorporation N.A

RVMD

Argus Research

a year ago

Market Digest: NVO, ADP, MSFT, ROP, SWKS, WY, ZION, MA

RVMD

Thomson Reuters StreetEvents

a year ago

Q4 2023 Unum Group Earnings Call

Unum Group (UNM) Q4 2023 Earnings Call Transcript

RVMD

Motley Fool

a year ago

Unum Group (UNM) Q4 2023 Earnings Call Transcript

BJ's Wholesale (BJ) Rides on Membership Surge & Digital Drive

RVMD

Zacks

a year ago

BJ's Wholesale (BJ) Rides on Membership Surge & Digital Drive

Division CEO A Anderson Sells Shares of Zions Bancorp NA

RVMD

GuruFocus.com

a year ago

Division CEO A Anderson Sells Shares of Zions Bancorp NA

Allison Transmission (ALSN) Ascends While Market Falls: Some Facts to Note

RVMD

Zacks

a year ago

Allison Transmission (ALSN) Ascends While Market Falls: Some Facts to Note

RVMD

Insider Monkey

a year ago

12 Stocks to Buy at a Discount Now

HR Software Q3 Earnings: Paycor (NASDAQ:PYCR) Simply the Best

RVMD

StockStory

a year ago

HR Software Q3 Earnings: Paycor (NASDAQ:PYCR) Simply the Best

RVMD

Thomson Reuters StreetEvents

a year ago

Q4 2023 Invesco Ltd Earnings Call

Invesco Canada announces cash distributions for its ETFs

RVMD

CNW Group

a year ago

Invesco Canada announces cash distributions for its ETFs

MakeMyTrip (MMYT) Tops Q3 Earnings and Revenue Estimates

RVMD

Zacks

a year ago

MakeMyTrip (MMYT) Tops Q3 Earnings and Revenue Estimates

Invesco Reports Results for the Three Months and Year Ended December 31, 2023

RVMD

PR Newswire

a year ago

Invesco Reports Results for the Three Months and Year Ended December 31, 2023

New York Times (NYSE:NYT) shareholders have earned a 14% CAGR over the last five years

RVMD

Simply Wall St.

a year ago

New York Times (NYSE:NYT) shareholders have earned a 14% CAGR over the last five years

Annaly Capital Management Inc (NLY) is Attracting Investor Attention: Here is What You Should Know

RVMD

Zacks

a year ago

Annaly Capital Management Inc (NLY) is Attracting Investor Attention: Here is What You Should Know

Annaly Capital Management, Inc. Announces Dates of Fourth Quarter 2023 Financial Results and Conference Call

RVMD

Business Wire

a year ago

Annaly Capital Management, Inc. Announces Dates of Fourth Quarter 2023 Financial Results and Conference Call

RVMD

Zacks

a year ago

Latest Revolution Medicines Inc. (RVMD) News on December 22, 2024

Share on Social Networks: